331 related articles for article (PubMed ID: 19803632)
1. The association between the negative effects attributed to ecstasy use and measures of cognition and mood among users.
Fisk JE; Montgomery C; Murphy PN
Exp Clin Psychopharmacol; 2009 Oct; 17(5):326-36. PubMed ID: 19803632
[TBL] [Abstract][Full Text] [Related]
2. An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users.
Pirona A; Morgan MJ
J Psychopharmacol; 2010 Feb; 24(2):175-85. PubMed ID: 19351799
[TBL] [Abstract][Full Text] [Related]
3. Is emotional intelligence impaired in ecstasy-polydrug users?
Craig L; Fisk JE; Montgomery C; Murphy PN; Wareing M
J Psychopharmacol; 2010 Feb; 24(2):221-31. PubMed ID: 18801831
[TBL] [Abstract][Full Text] [Related]
4. Self reported sleep quality and cognitive performance in ecstasy users.
Montgomery C; Fisk JE; Wareing M; Murphy P
Hum Psychopharmacol; 2007 Dec; 22(8):537-48. PubMed ID: 17960556
[TBL] [Abstract][Full Text] [Related]
5. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
6. Self-reports of executive dysfunction in current ecstasy/polydrug Users.
Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N
Cogn Behav Neurol; 2012 Sep; 25(3):128-38. PubMed ID: 22960437
[TBL] [Abstract][Full Text] [Related]
7. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
[TBL] [Abstract][Full Text] [Related]
8. Evidence for executive deficits among users of MDMA (Ecstasy).
Fisk JE; Montgomery C; Murphy P; Wareing M
Br J Psychol; 2004 Nov; 95(Pt 4):457-66. PubMed ID: 15527532
[TBL] [Abstract][Full Text] [Related]
9. Everyday and prospective memory deficits in ecstasy/polydrug users.
Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N
J Psychopharmacol; 2011 Apr; 25(4):453-64. PubMed ID: 20123936
[TBL] [Abstract][Full Text] [Related]
10. Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds.
Bedi G; Redman J
Psychol Med; 2008 Sep; 38(9):1319-30. PubMed ID: 18226286
[TBL] [Abstract][Full Text] [Related]
11. Everyday memory deficits in ecstasy-polydrug users.
Montgomery C; Fisk JE
J Psychopharmacol; 2007 Sep; 21(7):709-17. PubMed ID: 17606476
[TBL] [Abstract][Full Text] [Related]
12. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective.
Medina KL; Shear PK; Corcoran K
J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911
[TBL] [Abstract][Full Text] [Related]
13. Metamemory in recreational ecstasy polydrug users: what do self-reports of memory failures mean?
Bedi G; Redman J
J Psychopharmacol; 2008 Nov; 22(8):872-81. PubMed ID: 18208933
[TBL] [Abstract][Full Text] [Related]
14. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
[TBL] [Abstract][Full Text] [Related]
15. Male and female ecstasy users: differences in patterns of use, sleep quality and mental health outcomes.
Ogeil RP; Rajaratnam SM; Broadbear JH
Drug Alcohol Depend; 2013 Sep; 132(1-2):223-30. PubMed ID: 23453259
[TBL] [Abstract][Full Text] [Related]
16. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.
Indlekofer F; Piechatzek M; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG
J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709
[TBL] [Abstract][Full Text] [Related]
17. Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use.
Bedi G; Van Dam NT; Redman J
J Psychopharmacol; 2010 Feb; 24(2):233-40. PubMed ID: 18832429
[TBL] [Abstract][Full Text] [Related]
18. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
19. The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic?
Fisk JE; Montgomery C; Wareing M; Murphy PN
Hum Psychopharmacol; 2006 Aug; 21(6):355-66. PubMed ID: 16915582
[TBL] [Abstract][Full Text] [Related]
20. The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans.
Huxster JK; Pirona A; Morgan MJ
J Psychopharmacol; 2006 Mar; 20(2):281-90. PubMed ID: 16510486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
